Table S1. IFN-γ responses in individuals cured from VL at 24 hours, 72 hours, and 6 days after stimulation of whole blood *ex vivo* with candidate vaccine antigens (peptide pools; 5 μg/mL), SLA (10 μg/mL), PPD (5 μg/mL), or mitogen PHA (5 μg/mL). IFN-γ levels were measured by ELISA. Percent identity with *L. infantum* sequence at the amino acid level is indicated below candidate vaccine antigens (R71, Q51, etc.), which were originally derived from *L. major* [1].

	Mitogen or *Leishmania* Antigen																																
	PHA	PPD	SLA	R71 100%			Q 51 100%			L37 99%			N52 94%			L302.06 90%			J89 87%			M18 78%			J41 73%			M22 61%			M63 54%			M 57 35%		
S.N.				24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6	24 hrs	72 hrs	Day-6
PT-1	++++	-	+	-	-	-	-	-	-	-	-	-	+	+	+	+	-		-		+	+	-	-	+	-	+	+	-	-	-	-	-	-
PT-2	+++++	+++	+++	+	-	++	-	-	-	+	-	+	+	-	-	++	+	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-	++	+	-
PT-3	+++++	++	++	+	-	-	+	-	-	+	-	-	+	-	-	-	-	-	+	-	-	+	-	-	+	-	+	+	-	-	+	-	-	-	-
PT-4	+++++	-	++++	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+	-	-	-	-	-	-	-
PT-5	++++	++++	++	+++	+	-	-	-	-	+	+	-	+	+	-	-	-	-	+	-	-	+	-	-	+	-	-	-	-	-	-	+	+	-	-	-
PT-6	++++	-	++	++	+	+	-	+	-	+	+	++	++	+	-	-	-	-	+	+	-	-	-	-	-	+	+	++	+	-	+	+	-	-	-	-
PT-7	++++	+	++++	+	++	+	-	-	-	+	+	+	+	+	-	-	-	-	-	+	-	+	+	-	+	+	-	+		-	+	-	-	-	-	-
PT-8	+++++	++++	++	++	+	+	-	-	-	+	-	+	+		-	-	-	-	-	-	-	-		-	+	+	+	+	+	-	-	-	-	-	-	-
PT-9	+++++	+	++	+	+	++	+	+	-	+	+	+++	+	++	-	-	-	-	-	+	-	-	+	-	-	+	+++	+	+	-	-	+	-	+	-	-
PT-10	++++	+	++	+	+	-	-	-	-	-	-	+	+		-	-	+	-	-	+	-	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-
PT-11	++++	+	++++	+	+	-	-	-	-	-	+	++	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	+	+	-	-	-	-	-	-	-
PT-12	+++++	+	++++	+++	++	+	-	+	-	-	+	++	++	+	-	-	-	+	-	-	-	-	+	-	+	+	-	++	+	-	-	-	-	-	-	+
PT-13	++++	-	+	+	++	-	-	+	-	-	+	+	+		-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-
PT-14	+++++	+	++++	+	+	-	-	-	-	-	+	++	+	+	-	+	+	+	-	-	-	-	+	-	+	+	-	++	+	+	-	-	+	-	-	-	+
PT-15	+++++	+++	+	+	+	++	+	+	-	+	+	++	+	-	-	-	-	-	-	-	-	-	-	-	++	+	++	+	+	-	-	-	-	+	-	-
PT-16	++++	+	+++	+	+	+	-	-	-	+	+	++	+	-	-	+	+	+	-	-	-	-	-	-	+	+	+	+	-	-	-	-	-	+	-	+
	100 %	75 %	100 %	87.5%	75.0%	50.0%	18.7%	31.2%	0%	56.2%	62.5%	81.2%	87.5%	53.8%	6.2%	25%	25%	18.7%	18.5%	26.6%	6.2%	37.5%	26.6%	0%	68.7%	75.0%	37.5%	81%	46.6%	6.2%	25%	18.7%	12.5%	25%	6.2%	18.7%

- = <20pg/ml; + = 20-100pg/ml; ++ =100-250; +++ = 250-500pg/ml; ++++ = 500-10000pg/ml; ++++ = >10000pg/ml;
PHA = Phytohaemagglutinin; PPD = purified protein derivative from *Mycobacterium tuberculosis*; SLA = Soluble Leishmania antigen

1. Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, et al. (2006) From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24: 2602-2616.